financetom
Business
financetom
/
Business
/
Elon Musk’s share in Twitter is 'meaningless,' says big Tesla shareholder. But is it?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Elon Musk’s share in Twitter is 'meaningless,' says big Tesla shareholder. But is it?
Apr 7, 2022 12:08 PM

Elon Musk’s recent purchase of a 9.2 percent stake in Twitter may have moved the prices of the social media company’s stock, but for one Tesla investor, the investment is “meaningless.” Ron Baron, the CEO of Baron Capital, is one of Tesla’s biggest shareholders but he thinks that Musk’s investment in Twitter and his resulting board seat does not amount to much.

Share Market Live

NSE

“I think it’s meaningless,” he told CNBC. “It’s a tiny investment. $3 billion for a man who is worth $300 billion. He has Tesla which is worth a trillion (and) on the way to being worth $3 or $4 trillion.”

Also read: Elon Musk is on Twitter board: What does it mean for the microblogging site?

“There’s no way this could be anything meaningful to him,” added the long-term Tesla bull.

Though Twitter shares rose by 27 percent after Musk’s announcement, Baron’s company had chosen to not invest in the social media giant. Twitter’s stock has long underperformed when compared to other tech giants like Meta, Alphabet, Apple and others.

But Musk’s investment marks another instance of a centi-billionaire breaking into media organisations, even though many would not like to characterise Twitter as one. Musk, with his strong opinions, is expected to bring changes to how the social media platform is run.

Also read: Elon Musk has been working on 'Master Plan Part 3'; what could it be about?

Will Musk bring back Trump?

Twitter’s boardroom may be transforming into a tense battleground for different interests. Apart from Musk’s influential presence, other major presences in the Twitter boardroom are activist investor Elliott Management and Silver Lake’s Egon Durban.

One expected change that Elon Musk is expected to bring to the platform is the relaxation of its content policy over what is allowed and what is not, according to observers and experts. One such instance of ‘relaxation’ may be the lifting of the lifetime ban on former President Donald Trump, Anupam Chander, a professor in global internet regulation at Georgetown University told Financial Times.

Also read: Elon Musk posts poll on Twitter edit button; CEO Parag Agrawal warns of 'consequences'

Trump had been banned off the platform for his inflammatory statements, which led to the January 6 Capitol Hill insurrection that happened in the wake of his loss in the 2020 US presidential elections.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Wind tower maker Broadwind tops Q3 revenue estimates, lifts guidance
Wind tower maker Broadwind tops Q3 revenue estimates, lifts guidance
Nov 13, 2025
Overview * Broadwind ( BWEN ) Q3 revenue grows 25% yr/yr, beating analyst expectations * Company reports GAAP net income of $7.5 mln for Q3 2025 * Broadwind ( BWEN ) raises full-year 2025 revenue guidance Outlook * Broadwind ( BWEN ) raises full-year 2025 revenue guidance to $155 mln-$160 mln * Company received $11 mln in new tower orders...
Power transmitter Hydro One's Q3 revenue up 4.9%
Power transmitter Hydro One's Q3 revenue up 4.9%
Nov 13, 2025
Overview * Hydro One ( HRNNF ) Q3 revenue increased C$107 mln yr/yr, driven by higher demand and rates * Basic EPS for Q3 rose to C$0.70 from C$0.62 in 2024 * Company broke ground on St. Clair Transmission Line Project in southwestern Ontario Outlook * Company continues to invest in infrastructure to support growing electricity demand in Ontario *...
Applied Therapeutics Q3 net loss of $19 mln beats expectations
Applied Therapeutics Q3 net loss of $19 mln beats expectations
Nov 13, 2025
Overview * Applied Therapeutics ( APLT ) Q3 net loss of $19 mln beats analyst expectations * Company's Q3 operating income also beats analyst expectations * Research and development expenses decreased by $5.2 mln compared to Q3 2024 Outlook * Company to meet FDA in 4Q 2025 on govorestat for Classic Galactosemia * Company plans further FDA meeting for Phase...
Evoke Pharma Q3 sales rise 61%, expects QOL Medical acquisition to close in Q4 2025
Evoke Pharma Q3 sales rise 61%, expects QOL Medical acquisition to close in Q4 2025
Nov 13, 2025
Overview * Evoke Q3 2025 net product sales rose 61% yr/yr to $4.3 mln * Company to be acquired by QOL Medical for $11.00 per share * Gimoti patent extended to November 2038, ensuring exclusivity Outlook * Company expects acquisition by QOL Medical to close in Q4 2025 * Company anticipates expanded distribution through new pharmacy relationships * Company believes...
Copyright 2023-2026 - www.financetom.com All Rights Reserved